A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)

Clinical trial NCT05254899 · COMPLETED

Trial details

NCT number: NCT05254899
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Extranodal NK-T-Cell Lymphoma Early-stage High-Risk Cancer

Start date: 2021-11-10
Primary completion: 2025-08-30
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.